Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review

Dow Jones12-16 19:28

By Colin Kellaher

Shares of Aldeyra Therapeutics were sharply lower in premarket trading Tuesday after the biotechnology company said the U.S. Food and Drug Administration's review of its proposed reproxalap treatment for dry-eye disease has been extended by three months.

Aldeyra late Monday said that the FDA has extended its target action date for a decision on reproxalap to March 16, 2026, after the Lexington, Mass., company last week submitted a report on a dry-eye-disease field trial of reproxalap, which the agency deemed a major amendment to the application seeking approval of the drug.

Aldeyra shares, which closed Monday at $3.99, were recently down 15% at $3.39 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 16, 2025 06:28 ET (11:28 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591861189?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591861189","market":"other","top_or_hot":-1,"title":"Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Aldeyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> were sharply lower in premarket trading Tuesday after the biotechnology company said the U.S. Food and Drug Administration's review of its proposed reproxalap treatment for dry-eye disease has been extended by three months. \n</p>\n<p>\n  Aldeyra late Monday said that the FDA has extended its target action date for a decision on reproxalap to March 16, 2026, after the Lexington, Mass., company last week submitted a report on a dry-eye-disease field trial of reproxalap, which the agency deemed a major amendment to the application seeking approval of the drug. \n</p>\n<p>\n  Aldeyra shares, which closed Monday at $3.99, were recently down 15% at $3.39 in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2025 06:28 ET (11:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aldeyra Shares Fall Premarket After FDA Extends Reproxalap Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAldeyra Shares Fall Premarket After FDA Extends Reproxalap Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-16 19:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Aldeyra <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> were sharply lower in premarket trading Tuesday after the biotechnology company said the U.S. Food and Drug Administration's review of its proposed reproxalap treatment for dry-eye disease has been extended by three months. \n</p>\n<p>\n  Aldeyra late Monday said that the FDA has extended its target action date for a decision on reproxalap to March 16, 2026, after the Lexington, Mass., company last week submitted a report on a dry-eye-disease field trial of reproxalap, which the agency deemed a major amendment to the application seeking approval of the drug. \n</p>\n<p>\n  Aldeyra shares, which closed Monday at $3.99, were recently down 15% at $3.39 in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2025 06:28 ET (11:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALDX","symbol_name":"Aldeyra Therapeutics Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2591861189","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591861189","pubTimestamp":1765884480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Aldeyra Therapeutics were sharply lower in premarket trading Tuesday after the biotechnology company said the U.S. Food and Drug Administration's review of its proposed reproxalap treatment for dry-eye disease has been extended by three months.Aldeyra late Monday said that the FDA has extended its target action date for a decision on reproxalap to March 16, 2026, after the Lexington, Mass., company last week submitted a report on a dry-eye-disease field trial of reproxalap, which the agency deemed a major amendment to the application seeking approval of the drug.Aldeyra shares, which closed Monday at $3.99, were recently down 15% at $3.39 in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","BK4139":"生物科技"},"translate_title":"FDA延长Reproxalap审查后，Aldeyra股价盘前下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALDX":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Shares of Aldeyra Therapeutics were sharply lower in premarket trading Tuesday after the biotechnology company said the U.S. Food and Drug Administration's review of its proposed reproxalap treatment for dry-eye disease has been extended by three months. \n\n\n  Aldeyra late Monday said that the FDA has extended its target action date for a decision on reproxalap to March 16, 2026, after the Lexington, Mass., company last week submitted a report on a dry-eye-disease field trial of reproxalap, which the agency deemed a major amendment to the application seeking approval of the drug. \n\n\n  Aldeyra shares, which closed Monday at $3.99, were recently down 15% at $3.39 in premarket trading. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 06:28 ET (11:28 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591861189","isCrawlerRequest":true}